BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 17, 2026
Home » Topics » Science » Biomarkers

Biomarkers
Biomarkers RSS Feed RSS

Silhouette of head and brain with DNA double helixes
Neurology/psychiatric

Two copies of APOE4 cause genetic form of Alzheimer’s

May 6, 2024
By Anette Breindl
Based on its analysis of a large cohort of individuals homozygous for the ε4 variant of apolipoprotein E (APOE4), a multinational team of researchers is arguing that homozygosity for APOE4 should be considered a genetic form of Alzheimer’s disease. However, not everyone agrees that the findings warrant reclassifying APOE from risk factor to causal gene. Currently, APOE4 is classified as the strongest risk factor for developing AD. Another variant, the APOE2 variant, is protective, while APOE3 is neutral.
Read More
Neurology/psychiatric

Two copies of ApoE4 cause genetic form of Alzheimer’s

May 6, 2024
By Anette Breindl
Based on its analysis of a large cohort of individuals homozygous for the ε4 variant of apolipoprotein E (ApoE4), a multinational team of researchers is arguing that homozygosity for ApoE4 should be considered a genetic form of Alzheimer’s disease (AD).
Read More
Tiger mosquito
Biomarkers

sST2 as prognostic biomarker for severe dengue in adult patients

May 2, 2024
Researchers from Tan Tock Seng Hospital presented data from a study investigating the utility of soluble suppressor of tumorigenicity-2 (sST2) as early prognostic biomarker of severe dengue.
Read More
Illustration of tick penetrating skin into blood stream
Biomarkers

MCP-3 predicts prognosis of severe fever with thrombocytopenia syndrome

April 30, 2024
Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne disease that results from an infection with the SFTS virus, with a case fatality rate of 6.1% to 21.8%. Identifying critically ill patients at the early stages is crucial for clinical management.
Read More
Biomarkers

CD169 is a diagnostic marker of West Nile virus infection

April 29, 2024
About 25% of subjects with West Nile virus (WNV) infection develop fever and about 1% have neuroinvasive disease. Recent research has proposed measuring CD169 in peripheral blood (monocyte/lymphocyte ratio) as a marker of viral infections. The usefulness of monocyte CD169 (mCD169) in peripheral blood was tested in subjects with active WNV infection.
Read More
Lymph nodes
Biomarkers

ZNF334 down-regulation linked to lymph node metastasis in lung squamous cell carcinoma

April 24, 2024
Lung cancer is still among the deadliest cancers worldwide, with squamous cell carcinoma (SCC) of the lung accounting for about 30% of the cases. When the cancer metastasizes to the lymph nodes, the patient has a worse overall survival.
Read More
Medically accurate illustration of a baby in the womb of a pregnant mother
Cardiovascular

Peripartum cardiomyopathy is associated with placental senescence

April 24, 2024
By Mar de Miguel
Scientists at Massachusetts General Hospital have linked the risk of heart failure during pregnancy and senescence proteins produced by placental aging, which could clarify how peripartum cardiomyopathy (PPCM) is triggered and opens the door to the development of cardiac function therapies in late pregnancy.
Read More
DNA sequencing
Biomarkers

Mutation in DAAM2 causes steroid-resistant nephrotic syndrome

April 19, 2024
Steroid-resistant nephrotic syndrome (SRNS) is a disease characterized by hypoalbuminemia, proteinuria, edema and hyperlipidemia, and a cause of chronic kidney disease in the pediatric population.
Read More
Illustration of kidney with DNA structures
Biomarkers

Mutation in the UMOD gene tied to autosomal dominant tubulointerstitial kidney disease

April 18, 2024
Unknown etiology is commonly encountered in the kidney pre-transplant routine program. A screening program was performed to detect patients and study recipients that meet the following features: hypertension with no clear etiology and biopsies that do not match with clinical features of classical glomerulopathies.
Read More
Biomarkers

KANK2 G690C genetic variant tied to nephrotic syndrome and FSGS

April 17, 2024
Nephrotic syndrome is a kidney disorder characterized by abnormal functioning of the glomerular filtration barrier, and is frequently caused by focal segmental glomerulosclerosis (FSGS). At the World Congress of Nephrology meeting this week, researchers presented a case report of a 32-year-old female patient with nephrotic syndrome caused by FSGS diagnosed when she was 27.
Read More
Previous 1 2 … 17 18 19 20 21 22 23 24 25 … 269 270 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 16, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • In the clinic for June 12, 2026

    BioWorld
    Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing